Croda shares fall on weaker cash Flow despite in-line profit, reaffirmed outlook

Croda International shares fell over 4% following its H1 2025 results, primarily due to a sharp decline in operating cash flow to £96.5 million (from £194.5 million) and free cash flow to £34.2 million (from £122.7 million), coupled with an increase in net debt to £580 million (1.5x EBITDA). This negative cash flow and debt performance overshadowed the company's adjusted profit before tax of £138 million, which was in line with analyst expectations, and its reiteration of full-year guidance, indicating market concern over liquidity and leverage despite stable earnings.

Analysis

Croda International's first-half 2025 results triggered a more than 4% share price decline, indicating that investors are prioritizing liquidity and balance sheet health over in-line profit performance. The primary concern stems from a sharp deterioration in cash flow, with operating cash flow falling to £96.5 million from £194.5 million year-over-year due to working capital outflows, and a corresponding decline in free cash flow to £34.2 million. This has contributed to a rise in net debt to £580 million, representing a leverage of 1.5 times EBITDA. These negative developments overshadowed the fact that adjusted profit before tax of £138 million met consensus forecasts and that the company reiterated its full-year guidance. While the constant currency guidance of £265-£295 million was maintained, an updated £9.5 million foreign exchange headwind brings the effective range to £255-£285 million, which still encapsulates the £272 million consensus. The operational picture is mixed: the Life Sciences division outperformed expectations with a 320 basis point margin expansion, but the larger Consumer Care segment's EBIT fell 2% short of consensus. Management's proactive expansion of its cost-saving program to £100 million by 2027 signals an attempt to bolster future profitability amidst what analysts at Morgan Stanley term an "uncertain macro backdrop."

Key Decisions for Investors

• Investors should closely scrutinize Croda's working capital management in the coming quarters to determine if the significant H1 cash outflow is a temporary anomaly or a persistent operational issue.
• The divergence in divisional performance warrants attention; long-term value will depend on whether the outperformance and margin expansion in Life Sciences can sustainably offset the underperformance in the larger Consumer Care division.
• Given the stable profit outlook but deteriorating cash flow and increased leverage, investors should re-evaluate the stock's risk profile, as the market may demand a higher risk premium until balance sheet and liquidity metrics improve.
• Monitor progress against the expanded £100 million cost-saving initiative, as its successful execution is a key catalyst for protecting margins and achieving the reiterated full-year profit guidance.